Consumer legal funding, part of the personal injury ecosystem, is back in the spotlight. Not because the product has fundamentally changed. But because state legislatures nationwide continue to revisit how it should be defined, disclosed and regulated.
For physicians and attorneys working in personal injury, this legislative activity can feel too murky to get a handle on. But in practice, how consumer legal funding is treated in statutes affects case pacing, patient access to care, administrative burden and ultimately recovery outcomes.
A Familiar Pattern in Legislative Activity
At the time of publication of this article, 30+ state bills involving consumer legal funding or related litigation-finance issues are active nationwide, spanning jurisdictions from coast to coast. The Alliance for Responsible Consumer Legal Funding (ARC) has categorized a majority of these proposals as concerning for the consumer legal funding industry, often due to rate caps, disclosure requirements and/or loan-based classification frameworks.
Most state bills touching consumer legal funding tend to fall into recurring categories:
- Classification efforts, often debating whether consumer legal funding should be treated as a loan or as a non-recourse financial product.
- Disclosure-focused proposals, aimed at defining what information must be shared, and with whom.
- Rate-cap discussions, frequently borrowing language from traditional lending frameworks.
- “Clean-up” or clarification bills, designed to align existing statutes with prior regulatory intent.
- Bills aimed at commercial litigation finance that inadvertently sweep consumer legal funding into their scope.
This pattern isn’t new. What is changing, however, is the volume and velocity of these proposals, particularly as consumer legal funding is increasingly conflated with large-scale commercial litigation finance — a very different product serving a very different market.
That conflation is at the heart of much of today’s legislative confusion.
Conflation’s Very Real Consequences
Consumer legal funding exists to support injured individuals while their cases move through an often-slow legal process. It is non-recourse, meaning repayment depends entirely on the outcome of the case. Commercial litigation finance, by contrast, typically involves institutional capital backing complex corporate disputes.
When legislation fails to distinguish between the two, it can create downstream issues that matter directly to care providers and attorneys, including:
- Operational uncertainty for funding providers and servicers
- Delays or restrictions that affect a patient’s ability to continue treatment
- Increased administrative friction for law firms managing disclosures and compliance
- Confusion in courts, where disclosure rules may not align with discovery standards
What’s Actually Changing — and What Isn’t
Despite the steady drumbeat of legislation, a few important realities remain consistent:
- Consumer legal funding is already regulated in many states, often through non-recourse or specialty frameworks
- Most bills do not eliminate consumer legal funding, but attempt to reshape definitions, disclosures and/or oversight
- Many proposals stall or are revised significantly once operational realities are better understood
Industry organizations like ARC regularly publish educational resources explaining how consumer legal funding differs from loans and from litigation finance more broadly. ARC’s public commentary has emphasized that clarity — not over-correction — is what ultimately protects consumers while preserving access to care.
Trade publications also covering the space, including Legal Funding Journal (LFJ), warn proposals which blur the line between consumer legal funding and other financial or commercial models can carry unintended consequences. In its analysis of recent joint-liability proposals, LFJ notes measures designed to address perceived abuses in unrelated financing structures risk restricting access to legitimate, non-recourse consumer legal funding — particularly for injured individuals who rely on it to continue medical care while their cases proceed.